Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab + Tislelizumab + BAT1706 vs Tislelizumab + BAT1706 in first-line advanced hepatocellular carcinoma
CTR20211546Phase 2Completed
- Sponsor
- BeiGene
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ociperlimab, tislelizumab, RPH-001 in hepatocellular carcinoma (HCC), sponsored by BeiGene. Started Jul 2021; status: completed.
02
Drugs
ociperlimabtislelizumabRPH-001
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20211546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211546.